prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jun 14, 2022
Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer
The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these patients.
prostate cancer | Research | Treatment | 10 pages | source: PLOS ONE | Added Jun 05, 2022
Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer
This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary function compared to C-RARP, but with a higher risk of leaving cancer cells behind.
prostate cancer | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Jun 02, 2022
Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.
The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival without metastasis compared to ADT alone in these patients.
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added May 08, 2022
Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer progression and delaying PSA progression compared to AA for the treatment of patients with mCRPC.
prostate cancer | Research | Treatment | 10 pages | source: International Journal of Colorectal Disease | Added Apr 14, 2022
Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.
This study evaluated the risk of developing secondary rectal cancer after radiotherapy (RT) in patients with prostate cancer. The data showed that RT significantly increased the risk of developing secondary rectal cancer in these patients.
prostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Jan 30, 2022
Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.
This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these patients.
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jan 09, 2022
Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.
This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness.
prostate cancer | Research | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Nov 16, 2021
Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery
This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT.
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Nov 14, 2021
Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.
This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical, functional, and oncological outcomes compared to LRP in these patients.
prostate cancer | Research | 10 pages | source: The Lancet. Oncology | Added Nov 07, 2021
Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.
This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.